Apitoxin
PreclinicalSmall molecule
Apitoxin is one of 11 small molecule programs targeting Aphthous Ulcer. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Aphthous Ulcer
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Advil
KKenvue Brands
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Benadryl
PParkedale
Approved
Thalomid
Bristol-Myers SquibbPhase 2
Verazinc
FFakultas Kedokteran Universitas Indonesia
Phase 2
Peridex
MMedline Industries
Preclinical
Kenalog
MMichael Khazzam
Preclinical
Coenzyme Q10
MMclean Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Apitoxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTanta University